Beijing BioKanxin Biotechnology Completes New Round of RMB Strategic Financing with HAOYUE CAPITAL as Exclusive Financial Advisor

VCBeat has learned that Beijing Baicare Biotechnology Co., Ltd., a well-known domestic enterprise in the integrated microfluidic nucleic acid testing industry, has recently completed a new round of RMB strategic financing. The new investor in this round is Qianlong Investment, while existing shareholders have increased their holdings. Haoyue Capital served as the exclusive financial advisor for this financing round. The funds will be primarily used for the construction of new production facilities and the development of the company’s marketing system.

Beijing Baicare Biotechnology Co., Ltd., recognized as a National High-Tech Enterprise and a Zhongguancun High-Tech Enterprise, has received support from key projects deployed by the Chinese Academy of Sciences (CAS) and the National Science and Technology Major Project during the 13th Five-Year Plan period. The company has established close collaborative partnerships with Academician Zhong Nanshan’s team, the Guangzhou Institute of Respiratory Health, the Chinese Academy of Sciences, the Academy of Military Medical Sciences, and Peking Union Medical College Hospital. Holding multiple independent intellectual property rights, Baicare operates a 11,000-square-meter R&D and production center in Beijing and Tianjin. It has consecutively won awards such as the “Top 10 in the Zhongguancun International Frontier Technology Innovation Competition” and the “HICOOL Global Entrepreneurship Competition.”

With over a decade of deep expertise in the field of microfluidic chips, our team is committed to becoming a global leader in integrated molecular diagnostics and achieving comprehensive coverage of nucleic acid testing across all scenarios. We have currently established four major product lines catering to high-throughput outpatient and emergency settings, point-of-care testing (POCT), rapid community screening, and home-based mobile testing. Our independently developed products, including the “iChip-400 Isothermal Nucleic Acid Amplification Analyzer,” the “Respiratory Pathogen Nucleic Acid Detection Kit,” and the “Onestart-1000 Chip-Based Nucleic Acid Amplification Analyzer,” have all obtained Class III Medical Device Registration Certificates from the National Medical Products Administration. Our new product, the “Superone-8/16 Ultra-Rapid Extraction and Amplification Integrated System,” enables multi-sample testing within 30 minutes. All product lines are selling well both domestically and internationally, receiving strong market acclaim.

Driven by capital recognition and the need to expand production capacity, the company cordially invites talented individuals from all sectors who are dedicated, resilient, and ambitious to join us.

Mr. Zhang Guohao, Founder of BaicareIt stated that it is a great honor to receive the recognition and support of the investors in this round. Since its inception, Baicare has been positioned to develop and commercialize integrated molecular diagnostic systems. As the molecular diagnostics industry enters the era of automation, our accumulated expertise is increasingly coming to fruition. The support from both new and existing shareholders, along with the addition of top-tier domestic and international talent, has accelerated our growth. Our goal is to become a global leader, and our motto is “Higher, Faster, Stronger, Together.” We will continue to enhance our product capabilities, build our marketing brand, improve organizational management, and better serve users worldwide.

Mr. Ding Feng, Investment Director of Qianlong InvestmentIt was stated that since the outbreak of the COVID-19 pandemic, nucleic acid testing has become widely recognized as the gold standard for pathogen identification. However, the widespread adoption of PCR-based nucleic acid testing still faces numerous constraints, such as limited laboratory space, prolonged turnaround times preventing on-site results, and relatively complex operational procedures. As a pioneer in the development of integrated molecular diagnostic systems in China, Beijing Baicare Biotechnology Co., Ltd. boasts substantial expertise in its microfluidics technology platform. The company is leading domestically in both the regulatory submission and mass production progress of its multi-functional integrated devices. Upon completion of this financing round, Baicare is expected to accelerate the mass production of its integrated device cartridges, expedite its international expansion, and establish itself as an industry leader in integrated molecular diagnostics at an early stage.

Mr. Yao Yuan, Vice President of Haoyue CapitalWe are honored to serve as the exclusive financial advisor for Baicare’s current round of financing. In recent years, the integrated nucleic acid testing system sector has experienced rapid development, with international giants such as bioMérieux and Danaher actively establishing their presence in this field. The impact of the COVID-19 pandemic has further accelerated growth in this sector. As microfluidics and rapid amplification technologies are increasingly applied in clinical diagnostics, integrated nucleic acid testing systems will play a crucial role in rapid pathogen identification and guiding medication decisions. Beijing Baicare Biotechnology Co., Ltd. is a leading domestic player in the microfluidic integrated nucleic acid testing system industry. Given the technology’s high specificity, high sensitivity, high efficiency, and low cost, future products developed by the company can be widely used in both clinical and home settings, offering broad market prospects. Over the past year, the team has demonstrated exceptional execution capabilities and sustained innovation, making it a scarce and valuable asset in the domestic market. We are optimistic about Baicare’s growth potential and are honored to grow alongside such an outstanding enterprise.

Qianlong Investment focuses on investments in the healthcare sector, leveraging capital to propel the development of the biopharmaceutical industry. It consistently adheres to the investment philosophy of “research-driven value creation” and grows alongside outstanding enterprises with core competencies. Qianlong Investment concentrates on niche segments such as innovative drugs, diagnostics, vaccines, and pharmaceutical services. Its portfolio companies include Ascentage Pharma (HK06855), YHLO Biotech (SH688575), Allist Pharmaceuticals (SH688578), Biocytogen, GenScript, Zhuoyi Biologics, Xihua Testing, GenFleet Therapeutics, Zhongyi Anke, Kangsheng Medical, Starry Medical, and Beijing Baicare Biotechnology Co., Ltd.

Haoyue Capital was founded in January 2014, with a commitment to serving as a bridge connecting China’s healthcare sector with capital. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with extensive experience in China’s healthcare industry. By closely monitoring market dynamics and investment trends in the healthcare sector over the long term, the firm publishes weekly healthcare investment reports and thematic research studies, offering Haoyue’s perspectives on new policies and emerging frontiers.